PLA2G7

Jump to navigation Jump to search


Phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)
Identifiers
Symbols PLA2G7 ; PAFAH; LDL-PLA2
External IDs Template:OMIM5 Template:MGI HomoloGene3725
RNA expression pattern
File:PBB GE PLA2G7 206214 at tn.png
More reference expression data
Orthologs
Template:GNF Ortholog box
Species Human Mouse
Entrez n/a n/a
Ensembl n/a n/a
UniProt n/a n/a
RefSeq (mRNA) n/a n/a
RefSeq (protein) n/a n/a
Location (UCSC) n/a n/a
PubMed search n/a n/a

Phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma), also known as PLA2G7, is a human gene.[1]

The PLA2G7 gene encodes platelet-activating factor (PAF) acetylhydrolase (EC 3.1.1.47), a secreted enzyme that catalyzes the degradation of PAF to inactive products by hydrolysis of the acetyl group at the sn-2 position, producing the biologically inactive products LYSO-PAF and acetate.[supplied by OMIM][1]

References

  1. 1.0 1.1 "Entrez Gene: PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)".

Further reading

  • Schröder HC, Perovic S, Kavsan V; et al. (1998). "Mechanisms of prionSc- and HIV-1 gp120 induced neuronal cell death". Neurotoxicology. 19 (4–5): 683–8. PMID 9745929.
  • Feng Y, Walsh CA (2001). "Protein-protein interactions, cytoskeletal regulation and neuronal migration". Nat. Rev. Neurosci. 2 (6): 408–16. doi:10.1038/35077559. PMID 11389474.
  • Tjoelker LW, Eberhardt C, Unger J; et al. (1995). "Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad". J. Biol. Chem. 270 (43): 25481–7. PMID 7592717.
  • Tjoelker LW, Wilder C, Eberhardt C; et al. (1995). "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase". Nature. 374 (6522): 549–53. doi:10.1038/374549a0. PMID 7700381.
  • Tew DG, Southan C, Rice SQ; et al. (1996). "Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins". Arterioscler. Thromb. Vasc. Biol. 16 (4): 591–9. PMID 8624782.
  • Stafforini DM, Satoh K, Atkinson DL; et al. (1996). "Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase". J. Clin. Invest. 97 (12): 2784–91. PMID 8675689.
  • Yamada Y, Yokota M (1997). "Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation". Biochem. Biophys. Res. Commun. 236 (3): 772–5. doi:10.1006/bbrc.1997.7047. PMID 9245731.
  • Mavoungou E, Georges-Courbot MC, Poaty-Mavoungou V; et al. (1997). "HIV and SIV envelope glycoproteins induce phospholipase A2 activation in human and macaque lymphocytes". J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16 (1): 1–9. PMID 9377118.
  • Sapir T, Elbaum M, Reiner O (1998). "Reduction of microtubule catastrophe events by LIS1, platelet-activating factor acetylhydrolase subunit". EMBO J. 16 (23): 6977–84. doi:10.1093/emboj/16.23.6977. PMID 9384577.
  • Hiramoto M, Yoshida H, Imaizumi T; et al. (1998). "A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke". Stroke. 28 (12): 2417–20. PMID 9412624.
  • Yamada Y, Ichihara S, Fujimura T, Yokota M (1998). "Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men". Metab. Clin. Exp. 47 (2): 177–81. PMID 9472966.
  • Yoshida H, Imaizumi T, Fujimoto K; et al. (1998). "A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension". Thromb. Haemost. 80 (3): 372–5. PMID 9759612.
  • Lecointe N, Meerabux J, Ebihara M; et al. (1999). "Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma". Oncogene. 18 (18): 2852–9. doi:10.1038/sj.onc.1202645. PMID 10362256.
  • Kruse S, Mao XQ, Heinzmann A; et al. (2000). "The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma". Am. J. Hum. Genet. 66 (5): 1522–30. PMID 10733466.
  • Howard KM, Olson MS (2000). "The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats". J. Biol. Chem. 275 (26): 19891–6. doi:10.1074/jbc.M001462200. PMID 10748027.
  • Min JH, Wilder C, Aoki J; et al. (2001). "Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme". Biochemistry. 40 (15): 4539–49. PMID 11294621.
  • Quarck R, De Geest B, Stengel D; et al. (2001). "Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice". Circulation. 103 (20): 2495–500. PMID 11369691.
  • Unno N, Nakamura T, Mitsuoka H; et al. (2002). "Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese". Ann. Surg. 235 (2): 297–302. PMID 11807372.

Template:WikiDoc Sources